SUNNYVALE, Calif., Jan. 27, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Tom O'Neil has joined the company as Chief Financial Officer. Mr. O'Neil brings more than 15 years of industry experience to Sorbent. In this role, he will oversee Sorbent's financial operations, reporting directly to Detlef Albrecht, M.D., Sorbent's President and Chief Executive Officer.
"Tom brings significant experience in corporate finance and is a welcome addition to our leadership team," said Dr. Albrecht. "Tom brings key skills and expertise that are highly relevant to Sorbent's business today and to our future growth, including clinical-stage and commercial financial management, private and public financing, strategic planning, and a wide range of corporate development activities."
"With Phase 2b clinical data for CLP-1001 in heart failure expected later this year, this is an exciting time to join Sorbent," said Mr. O'Neil. "I look forward to working with Detlef, the management team and Sorbent's Board of Directors to help realize the full potential of CLP-1001 and other product candidates in Sorbent's pipeline."
Mr. O'Neil has more than 15 years of finance and operations experience in start-ups through large public companies. Previously, Mr. O'Neil was Vice President, Finance & Administration for ChemGenex Pharmaceuticals, a publicly traded Australian company, prior to its acquisition by Cephalon, Inc. (subsequently acquired by Teva Pharmaceuticals). Before ChemGenex, he was Vice President, Finance & Administration for venture capital-backed biotechnology start-ups, Nodality and HX Diagnostics. Prior to that, Mr. O'Neil held several finance roles at Monogram Biosciences, Inc. (acquired by LabCorp). Mr. O'Neil's experience includes the oversight and management of equity and debt financings, initial public offerings, merger and acquisitions, collaborations, and investor relations. He has an M.B.A. from the University of California, Los Angeles, Anderson Graduate School of Management, and a B.A. from Pomona College.
Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body. The company is focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, end-stage renal disease, chronic kidney disease and hypertension. Sorbent is headquartered in Sunnyvale, California. For more information, visit www.sorbent.com.
SOURCE Sorbent Therapeutics